icaria-MM: sarclisa + POMALIDOMIDE AND DEXAMETHASONE (Pd)
icaria-MM Patient
Profiles
Treating with sarclisa + Pd as early as
first relapse1
Current patient information
68 years of age
![](/assets/img/ikema-patient-profiles/Cytogenetic-icon.png)
High: t(4;14)
![](/assets/img/ikema-patient-profiles/ECOG-icon.png)
![](/assets/img/icaria-patient-profiles/Cardiovascular-icon.png)
ECG shows EF 45%,
uncontrolled hypertension
![](/assets/img/ikema-patient-profiles/Person-icon.png)
Diagnosis
![](/assets/img/ikema-patient-profiles/triangle-line-1.png)
Diagnosed 3 years ago after work-up for fatigue revealed anemia
1st line
![](/assets/img/ikema-patient-profiles/triangle-line-2.png)
VRd induction → ASCT → bortezomib and lenalidomide maintenance (CR for 30 months posttransplant)
1st relapse
![](/assets/img/ikema-patient-profiles/triangle-line-3.png)
Peripheral neuropathy; relapsed with new lesion in humerus found on MRI
2nd-line treatment considerations for Laura
![](/assets/img/ikema-patient-profiles/triangle-line-4.png)
- High cytogenetic risk
- Cardiovascular comorbidities
- Double refractory to lenalidomide and bortezomib
- Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®
consider sarclisa + Pd as early as first relapsefor patients with high cytogenetic risk and patients with cardiovascular
comorbidities1
PFS in the intent-to-treat population1
- mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)
This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.
ASCT=autologous stem cell transplant; CR=complete response; ECG=electrocardiogram; ECOG PS=Eastern Cooperative Oncology Group performance status; EF=ejection fraction; IMiD=immunomodulatory drug; mAb=monoclonal antibody; mPFS=median progression-free survival; MRI=magnetic resonance imaging; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.
PFS results in patients with high cytogenetic risk
and patients refractory to lenalidomide
In icaria-MM, 20% of patients had high cytogenetic risk* and 93%
were refractory to lenalidomide1
PFS in patients with high cytogenetic risk2,3
![](/assets/img/icaria-patient-profiles/Down-arrow-icon.png)
Reduction in the risk of
disease progression
HR=0.66 (95% CI: 0.33, 1.28)
![mPFS in patients with high cytogenetic risk: 7.5 months with SARCLISA + Pd vs 3.7 months with Pd alone.](/assets/img/icaria-patient-profiles/SARCLISA-PFS-high-cytogenetic-risk.png)
PFS in patients refractory to lenalidomide4
![](/assets/img/icaria-patient-profiles/Down-arrow-icon.png)
Reduction in the risk of
disease progression
HR=0.59 (95% CI: 0.43, 0.82)
![mPFS in patients refractory to lenalidomide: 11.4 months with SARCLISA + Pd vs 5.6 months with Pd alone.](/assets/img/icaria-patient-profiles/SARCLISA-PFS-refractory-to-lenalidomide.png)
See the full icaria-mm patient subgroup data
Study limitations
Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.
*Cytogenetics by central lab; cutoff 50% for del(17p), 30% for t(4;14) and t(14;16).3
![](/assets/img/icaria-patient-profiles/top-gradient.png)
Review the broad and diverse patient population studied in the phase 3 ICARIA-MM trial1
See ICARIA-MM Trial Design![](/assets/img/icaria-patient-profiles/bottom-gradient.png)
Current patient information
78 years of age
![](/assets/img/ikema-patient-profiles/Cytogenetic-icon.png)
Standard
![](/assets/img/ikema-patient-profiles/ECOG-icon.png)
![](/assets/img/ikema-patient-profiles/Person-icon.png)
![](/assets/img/ikema-patient-profiles/Renal-icon.png)
(eGFR)
48 mL/min/1.73 m2
Diagnosis
![](/assets/img/ikema-patient-profiles/triangle-line-1.png)
Diagnosed ~3.5 years ago after presenting with anemia, moderate renal insufficiency, mild hypercalcemia, and severe osteoporosis; transplant ineligible
1st line
![](/assets/img/ikema-patient-profiles/triangle-line-2.png)
VRd induction → lenalidomide maintenance (VGPR for 36 months); developed persistent peripheral neuropathy during induction
1st relapse
![](/assets/img/ikema-patient-profiles/triangle-line-3.png)
Relapse confirmed after consecutive labs showed increase of M-protein and light chains, recurrence of hypercalcemia, and reappearance of renal insufficiency
2nd-line treatment considerations for Ben
![](/assets/img/ikema-patient-profiles/triangle-line-4.png)
- Elderly
- Impaired renal function
- Refractory to lenalidomide
- Developed neuropathy from prior bortezomib treatment
- Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®
consider sarclisa + Pd as early as first relapsefor elderly patients and patients with impaired renal function1
PFS in the intent-to-treat population1
- mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)
This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.
ECOG PS=Eastern Cooperative Oncology Group performance status; eGFR=estimated glomerular filtration rate; IMiD=immunomodulatory drug; mAb=monoclonal antibody; M-protein=monoclonal protein; mPFS=median progression-free survival; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VGPR=very good partial response; VRd=bortezomib, lenalidomide, dexamethasone.
PFS results in elderly patients and
patients with impaired renal function
In icaria-MM, 20% of patients were elderly (≥75 years) and
36% had impaired renal function3*
PFS in elderly patients (≥75 years)2,3
![](/assets/img/icaria-patient-profiles/Down-arrow-icon.png)
Reduction in the risk of
disease progression
HR=0.48 (95% CI: 0.24, 0.95)
![mPFS in elderly patients aged ≥75 years: 11.4 months with SARCLISA + Pd vs 4.5 months with Pd alone.](assets/img/icaria-patient-profiles/SARCLISA-PFS-elderly-patients-aged-≥75-years.png)
PFS in patients with renal impairment2,3
![](/assets/img/icaria-patient-profiles/Down-arrow-icon.png)
Reduction in the risk of
disease progression
HR=0.50 (95% CI: 0.30, 0.85)
![mPFS in patients with renal impairment: 9.5 months with SARCLISA + Pd vs 3.7 months with Pd alone.](/assets/img/icaria-patient-profiles/SARCLISA-PFS-renal-impairment.png)
See the full icaria-mm patient subgroup data
Study limitations
Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.
*eGFR <60 mL/min/1.73 m2.1
![](/assets/img/icaria-patient-profiles/top-gradient.png)
Review the broad and diverse patient population studied in the phase 3 ICARIA-MM trial1
See ICARIA-MM Trial Design![](/assets/img/icaria-patient-profiles/bottom-gradient.png)